Skoči na glavni sadržaj

Stručni rad

CROATIAN SOCIETY FOR MEDICAL ONCOLOGY CLINICAL GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP OF PATIENTS WITH MELANOMA

Davorin Herceg
Daška Štulhofer Buzina
Romana Čeović
Snježana Dotlić
Ivana Ilić
Sanda Smuđ Orehovec
Gordana Horvatić Herceg
Davor Mijatović
Robert Šeparović
Tajana Silovski
Damir Vrbanec


Puni tekst: hrvatski pdf 989 Kb

preuzimanja: 2.936

citiraj


Sažetak

Melanoma in the Western world has an increasing incidence. One of the most important factor for the increase in incidence is sporadic, uncontrolled exposure to the sun. The basis for the treatment of primary melanoma is surgical treatment. Treatment of metastatic disease of melanoma in recent years experienced significant changes. BRAF and MEK inhibitors, immunotherapy with programmed cell-death immune checkpoint inhibitors (anti-PD-1-antibodies) are new ­options for the treatment of metastatic disease. A mulitidisiplinary team of Croatian Society for Medical Oncology provides recommendations for diagnosis, treatment and follow-up of melanoma primarily driven to the discovery of new drugs and therapeutic options, that change the prognosis of patients with metastatic melanoma.

Ključne riječi

Melanoma – diagnosis, pathology, therapy; Skin neoplasms – diagnosis, pathology, therapy; Neoplasm metastasis; Proto-oncogene proteins BRAF – antagonists and inhibitors; Protein kinase inhibitors; Antibodies, monoclonal; Programmed cell death 1 receptor – antagonists and inhibitors; Antineoplastic agents; Medical oncology – standards; Practice gudelines as topic; Croatia

Hrčak ID:

172819

URI

https://hrcak.srce.hr/172819

Datum izdavanja:

29.2.2016.

Podaci na drugim jezicima: hrvatski

Posjeta: 4.106 *